Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243752 | 0.80 | NR1I2 (0.33) | NR1I2 | |
| SCHEMBL1241912 | 0.80 | NR1I2 (0.50) | NR1I2 | |
| SCHEMBL1243677 | 0.77 | NSD2 (0.42) | NR1I2PBRM1POLB | |
| SCHEMBL1243685 | 0.75 | NR1I2 (0.62) | NR1I2LMNAMEN1KMT2APBRM1 | |
| SCHEMBL1244236 | 0.75 | NR1I2 (0.46) | NR1I2PBRM1 | |
| SCHEMBL12445707 | 0.72 | NR1I2 (0.80) | NR1I2 | |
| SCHEMBL1241891 | 0.72 | GRM2 (0.33) | NR1I2 | |
| SCHEMBL1244284 | 0.72 | NR1I2 (0.44) | NR1I2LMNAMEN1KMT2A | |
| SCHEMBL4687424 | 0.72 | LMNA (0.34) | LMNACES1 | |
| SCHEMBL12445706 | 0.71 | NR1I2 (0.62) | NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| EP-1915373-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | Merck and Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | NR1I2 417/4885LMNA 4389/4885NOTUM 1638/4885 |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPK7 | NR1I2 589/4885LMNA 4285/4885NOTUM 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.